electrovac Annual General Meeting: Growth Initiatives Progressing Well - Executive Board Reaffirms Raised Earnings Forecast for 2026/2027

Electrovac’s preliminary first-half FY2026/2027 revenue rose 10.4% to EUR 61.5 million, while EBIT increased 26.1% to EUR 8.2 million and margin expanded to 13.3%, including EUR 2.3 million of one-off IPO costs. The board reaffirmed its raised FY2026/2027 outlook of EUR 13–14 million EBIT (EUR 15–16 million adjusted for IPO costs) and unchanged revenue guidance of EUR 120–130 million. Growth initiatives advanced in Thailand, China, the US and Aerospace & Defense; the company said Aerospace & Defense capacity expansion was completed as its first roadmap milestone.

Analysis

The earnings signal is better than the headline growth rate: EBIT expanded faster than revenue despite IPO costs, suggesting operating leverage and/or a richer mix from Industrials and Aerospace & Defense. The key question is durability, not whether the first half was strong. Aerospace qualification and customer program ramps can take time; the company has started, but not completed, the cited certifications, so added capacity does not yet guarantee near-term shipments.

For the next 1–3 months, the reaffirmed outlook offers limited incremental catalyst unless order intake or guidance moves again. Watch whether second-half delivery supports the forecast without relying on temporary mix or cost timing. Over 6–18 months, Thailand’s planned line and US market entry create upside optionality but also execution, utilization, and investment risks; neither should be capitalized as near-term earnings yet. China localization may protect customer access, but with meaningful existing revenue exposure there, it also concentrates operational and geopolitical risk rather than diversifying it away.

Contrarian risk: investors may extrapolate first-half margin gains into a structural margin step-up before certifications, new-site economics, and customer ramps are proven. Conversely, if the reported EBIT figure includes the stated one-off IPO costs, underlying execution may be stronger than the unadjusted figure implies. Valuation, liquidity, order book, capex, and customer concentration are not provided, so conviction sizing or a price target is not supportable.

Key Decisions for Investors

• Treat the release as a positive fundamental confirmation, not a fresh earnings catalyst; avoid chasing without checking the share-price reaction, valuation, and trading liquidity.
• Set an alert for the next trading update and results: test revenue against the EUR 120–130m outlook and adjusted EBIT against EUR 15–16m, while separating recurring operating performance from IPO-related costs.
• Keep Thailand and US expansion as watch items, not forecast contributions yet. Reassess only after production starts, utilization and capex are disclosed, and US customer wins or qualified programs are evidenced.
• Monitor China site selection and localization execution alongside any change in regional demand or customer requirements. A material deterioration in China business or slippage in the earnings outlook would falsify the constructive thesis.